-
Clinical Significance of Serum C-Reactive Protein in Patients with Colorectal Cancer
-
Sung Chul Park, Yoon Tae Jeen, Kwang Gyun Lee, Juhyung Kim, Jong Jin Hyun, Eun Sun Kim, Sanghoon Park, Bora Keum, Yeon Seok Seo, Yong Sik Kim, Hoon Jai Chun, Soon Ho Um, Jai Hyun Choi, Chang Duck Kim, Ho Sang Ryu
-
Intest Res 2009;7(2):93-99. Published online December 30, 2009
-
-
-
 Abstract
 PDF
- Background/Aims
C-reactive protein (CRP) is a general marker of inflammation and increased CRP level is reported in several cancers. It has been reported that CRP is an independent factor predicting survival in colorectal cancer patients, although this claim is still under debate. The aim of this study was to investigate the association between CRP and the characteristics of colorectal cancer patients. Methods: One hundred eighty-four patients diagnosed with colorectal cancer between January 2007 and January 2009 were included. The patients with active infectious diseases, other tumors, cardiovascular disease, or inflammatory bowel disease were excluded. The CRP levels of colorectal cancer patients were compared with the control group comprised of 175 healthy adults with a normal colonoscopy. Results: The median CRP in the colorectal cancer patients (3.36 mg/L) was higher than the control group (0.48 mg/L). There was a significant correlation between CRP and the stage of colorectal cancer (p＜0.001). CRP was increased significantly in Dukes' stage D. CRP had a significant correlations with the CEA and CA 19-9 levels, the ESR, and the white blood cell count, and an inverse correlation with albumin. The CRP level in colon cancer patients was higher than rectal cancer patients (p=0.032). There were no significant difference in the CRP according to metastatic sites, such as the liver and peritoneum. Conclusions: Serum CRP levels were higher in patients with colorectal cancer and high CRP level is a predictor of advanced disease. (Intest Res 2009;7:93-99)
-
Calreticulin Expression in Colon Cancer and Adenoma with Western Blot Assay
-
Bora Keum, Yoon Tae Jeen, Sanghoon Park, Yeon Seok Seo, Yong Sik Kim, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Sang Woo Lee, Jai Hyun Choi, Chang Duck Kim, Ho Sang Ryu
-
Intest Res 2006;4(1):7-11. Published online June 30, 2006
-
-
-
Abstract
PDF
- Background/Aims
Colon cancer has a multistep process of molecular changes on the way of carcinogenesis. The detection of gene mutations associated with those molecular changes is expected to be able to predict or diagnose colon cancer. Calreticulin is one of the protein which has being investigated as a biomarker of colorectal cancer. The Aims of this study was to demonstrate the expression of calreticulin in normal colon mucosa, colonic tubular adenoma and colorectal cancer of each patient, and analyze the differences among them. Methods: 8 patients who have colorectal adenocarcinoma and more than 10 mm sized tubular adenoma synchronously were enrolled. Colorectal adenocarcinoma, tubular adenoma and normal colon tissue were taken from each patient. After proteins isolation and separation, western blot assay were performed to demonstrate calreticulin. The results were analyzed by Wilcoxon Signed Rank Test. Results: Calreticulin was more expressed in colorectal adenocarcinoma and tubular adenoma significantly compared with normal mucosa. Also, calreticulin was more expressed in adenocarcinoma than in adenoma but there were no significant diffences. Conclusions: These results suggest that calreticulin may be available for an early diagnostic biomarker for colorectal cancer or advanced colon adenoma. (Intestinal Research 2006;4:7-11)
|
KASID
